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Reduces Deep Vein Thrombosis Recurrence
F. Aziz, J. T. Chen, and A. J. Comerota, The Toledo Hospital, Toledo,
Ohio
Background: Iliofemoral deep vein thrombosis (DVT) is a result of a
major thrombotic stimulus that results in substantial postthrombotic mor-
bidity in patients treated with anticoagulation alone. It has been shown that
iliofemoral DVT is a powerful and independent risk factor for recurrent
thromboembolism. Furthermore, recurrent DVT escalates postthrombotic
morbidity, since recurrent DVT has been correlated with residual venous
thrombus. Eliminating thrombus in high-risk patients might reduce the risk
of recurrence. We reviewed the entire cohort of patients with iliofemoral
DVT treated with catheter-directed thrombolysis to determine their risk of
recurrence and whether there was a relationship to lytic success.
Methods: All patients who underwent catheter-based thrombus re-
moval for iliofemoral DVT had their degree of lysis assessed by comparison
of pre- and postprocedural phlebography and were classified according to
the percentage of residual thrombus. Recurrence was defined as a symptom-
atic presentation with image verification of new or additional thrombus.
Results: Sixty-two patients underwent catheter-directed thrombolysis
for iliofemoral DVT. Mean age was 45 17 years (range, 16-79 years), and
35 patients (56%) were male. Mean follow-up was 18.9 months and seven
patients (11%) were lost to follow up. Forty-eight patients (87%) had no
recurrence, and seven patients (13%) developed recurrent DVT. Recurrence
developed in 67% of patients who had60% residual thrombus but occurred
in 10% of those who had 60% residual thrombus (P  .0253). The seven
patients who developed recurrent DVT were anticoagulated at the time of
recurrence.
Conclusion: Patients who underwent either catheter-directed throm-
bolysis of iliofemoral DVT have lower incidence of recurrent deep vein
thrombosis as compared with historic groups who are treated by anticoag-
ulation alone. Furthermore, there is a direct correlation between the amount
of residual thrombus following catheter-based thrombolysis and recurrence.
As lytic success improves, the risk of recurrent DVT decreases. These data
raise the hypothesis that successful thrombolysis reduces recurrence rates,
which requires validation in prospective studies.
Creation of a Simple Venous Thromboembolism Risk Score for Out-
patient Surgery: Analysis of the National Surgical Quality Improve-
ment Program Database
C. J. Pannucci, A. Shanks, M.Moote, V. Bahl, P. Cederna, N. Naughton, P.
Henke, S. Kheterpal, and S. Campbell, The University of Michigan, Ann
Arbor, Mich
Background:Factors that contribute to venous thromboembolism
(VTE) risk after outpatient surgery are unknown. We used the National
Surgical Quality Improvement Program (NSQIP) database to examine risk
factors for VTE after outpatient surgery and empirically derive a VTE
risk-scoring model.
Methods: The NSQIP is a prospective database of surgical patients
with 30-day outcomes. Inclusion criteria for this analysis were age 18,
surgery classified as “outpatient,” and length of stay equal to zero days.
Independent variables included known VTE risk factors (Table). Age,
operative time, and body mass index were transformed to categorical vari-
ables to facilitate risk-score creation.
Trained NSQIP clinical nurses collect risk factor and adverse event data
using medical record review. Mandatory nurse-patient contact on postoper-
ative day 30 identifies complications treated at other hospitals. The NSQIP
defines deep vein thrombosis (DVT) as venous clots requiring either sys-
temic anticoagulation or inferior vena cava filter. Pulmonary embolus is
defined as an obstructing pulmonary arterial clot. Imaging is required for
DVT or pulmonary embolism (PE) diagnosis. The primary study outcome
was VTE, generated as a composite of DVT and/or PE.
Multivariable logistic regression identified independent risk factors.
-coefficients for independent predictors were used to derive a weighted
risk-scoringmodel; this was compared to the unweighted risk-scoringmodel
using the c-statistic.
Results: For this study, 168,518 patients met the inclusion criteria.
DVT incidence was 0.1% (172 patients), PE was 0.04% (38 patients), and
VTE was 0.12% (210 patients). Of patients with VTE, 1 in 10 (0.013%
overall) had both DVT and PE.
Independent predictors of VTE included arthroscopic surgery, current
pregnancy, active cancer, and invasive venous procedure. When compared
with the reference group, age 41 to 60 years, age60 years, bodymass index
40, and operative time 120 minutes were also independent predictors
(Table). The model accounted for 80% of the variability in VTE (c-statistic
0.800). The average time-to-event for both DVT and PE was postoperative
day 10  7.
C-statistic for weighted risk scores (0.76  0.02) was significantly
higher than the unweighted risk score (0.72  0.02). The weighted risk-
score model is shown in the Fig.
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surgery population using a simple risk-scoringmodel. Aggressive chemopro-
phylaxis may be considered in patients with higher risk. However, further
research is necessary to examine the risks, benefits, and cost of chemopro-
phylaxis for outpatient surgery.
Table.
Risk factor
Adjusted odds ratio
(95% CI) P value
Male gender 1.04 (0.77-1.40) .819
General anesthesia 1.38 (0.95-2.00) .091
Arthroscopic surgery 4.87 (2.88-8.21) .001
Abdominal laparoscopy 1.15 (0.72-1.82) .555
Current pregnancy 8.91 (1.11-71.24) .035
Active cancer 5.38 (2.33-12.41) .001
Congestive heart failure 3.73 (0.43-32.21) .231
Chronic obstructive
pulmonary disease
1.24 (0.49-3.13) .648
Diabetes requiring medication 0.86 (0.51-1.45) .567
Central vascular disease 1.40 (0.84-2.33) .192
Peripheral vascular disease 0.73 (0.17-3.14) .642
Current smoker 0.99 (0.67-1.46) .940
Renal failure on dialysis 0.70 (0.16-3.09) .636
Prior operation within 30 days 1.09 (0.40-2.99) .872
Invasive venous procedure 13.42 (9.56-18.84) .001
Age
40 years Reference —
41-60 years 1.98 (1.24-3.16) .004
60 years 2.57 (1.57-4.20) .001
Body mass index
25 Reference —
25-40 1.04 (0.74-1.45) .836
40 1.85 (1.10-3.09) .019
Total operative time
60 minutes Reference —
60-120 minutes 1.12 (0.82-1.52) 0.494
120 minutes 1.68 (1.02-2.77) 0.043
Vena-caval Filters: Review of Indications and Practices at a University
Hospital
R. J. Meisner, N. Labropoulos, A. P. Gasparis, and A. Tassiopoulos, Stony
Brook University Hospital, Stony Brook, NY
Background: Vena cava filter (VCF) use has been increasing in recent
years, particularly after the advent of retrievable filters. A significant number
of VCF appear to be utilized outside the defined indications for this
procedure. This so-called prophylactic VCF placement is particularly con-
troversial, as it is not supported by solid clinical data but is applied liberally in
“high-risk” patients (multiple trauma, morbid obesity). The aim of thisstudy was to investigate the current practice on VCF use at our own
institution.
Methods: Consecutive patients with VCF placement over a 2-year
period (2007 to 2009) at a university hospital were reviewed. Patient
demographics, filter type, retrieval, complications, indications for the pro-
cedure, and department performing the procedure were collected in all
patients.
Results: A total of 244 patients underwent VCF placement of which
159 were retrievable and 84 were permanent. Fifty-four percent of patients
had the VCF placed for an absolute indication, 14% for a relative indication,
and 32% for prophylaxis. Of those patients with a retrievable filter, only 14
(9%) had it removed. Eight patients had a complication of VCF placement,
while there were no complications of filter retrieval. Two of the eight
patients had a major complication: death and right ventricle injury. The
other six complications were considered minor, such as hematoma, filter
migration, and misdeployment. The Department of Trauma and Surgical
Critical Care (TSCC) placed the majority of VCF (n  107), followed by
Vascular Surgery (n  77) and Interventional Radiology (n  60). VCF
placement for prophylaxis alone without absolute indication was 57% from
the TSCC, 18.3% from Interventional Radiology (P  .0001), and 5.2%
from Vascular Surgery (P  .0001 compared with TSCC and P  .025
compared with Interventional Radiology).
Conclusions: The results of this study indicate that as many as 32% of
VCF placed are placed for prophylaxis. A very low percent of VCF is
retrieved. The majority of VCF at this university were placed by the TSCC.
These practices are not in accordance to strict evidence-based guidelines for
VCF placement. This is likely the practice at many other large US university-
based hospitals necessitating strategies for reducing their placement.
Venous Disease and the Effects of Increasing BodyMass Index: Results
from the National Venous Screening Program
C. J. Moore,a R. B. McLafferty,a M. Lentz,b J. R. Schneider,c A. Roupeni-
an,d J. Heller,e W. Bohannon,f and M. Passman,g The Southern Illinois
University, Springfield, Ill,a the National Venous Screening Program, Balti-
more, Md,b the Central Dupage Hospital, Winfield, Ill,c the Vein and Laser
Center NE, Plymouth, Mass,d the Johns Hopkins Vein Center,
Baltimore, Md,e the Scott and White Memorial Hospital and Clinic,
Temple, Tex,f and the University of Alabama, Birmingham, Ala.g
Objective: To determine differences in venous disease across a spec-
trum of body mass index (BMI) from participants in the National Venous
Screening Program (NVSP).
Methods: Utilizing the prospectively maintained database from the
NVSP, statistical analysis was performed to examine differences between
participants according to standard BMI group designations. Data points for
comparison included demographics, thromboembolic (venous thromboem-
bolism) risk assessment, venous quality of life (CIVIQ2), duplex evaluation,
CEAP classification, and venous clinical severity score. A P value of less than
0.01 was considered statistically significant.
Results: From 2005 to 2010, the NVSP has screened 7227 Americans.
BMI category distribution included underweight (UW; BMI 18.5) 1.3%;
normal weight (NW; BMI 18.5-24.9) 34.9%; overweight (OW; BMI 25-
29.9) 34.9%; obese (OB; BMI 30-34.9) 16.6%; morbidly obese (MOB;
BMI 35-39.9) 7.8%; and super morbidly obese (SMOB; BMI 40) 4.7%.
Significant increases in BMI occurred incrementally in diabetes (NW: 4.9%
to SMOB: 25.2%) and hypertension (NW: 22.9% to SMOB: 54.3%). Mean
venous thromboembolism risk assessment scores significantly increased in-
crementally (NW: 3.32 to SMOB: 4.12). Mean quality-of-life scores signif-
icantly increased incrementally (NW: 20.3 to SMOB: 29.02). This observa-
tion was related to differences in limitations of activity. Mean CEAP scores
demonstrated significant incremental increases (NW: 1.49, OW: 1.54, OB:
1.64, MOB: 1.86, SMOB: 2.01). Mean venous clinical severity score scores
significantly increased incrementally (NW: 2.80 to SMOB: 4.58). Duplex
data demonstrated a significantly higher percentage of common femoral vein
reflux in the UW group compared with the overweight classes (UW: 26.04%
to SMOB: 18.69%).
Conclusions: Americans participating in the NVSP show worsening of
venous disease across most objective measures as BMI increases. The pres-
ence of common femoral vein reflux appears to be less with increasing BMI,
and brings in to question the appropriateness of this limited duplex exami-
nation in this population versus calf-muscle pump dysfunction. As obesity
rates climb at a rapid rate, the morbidity and mortality from venous disease
could markedly worsen. This information remains vital across all levels of
health care and further provides objective data to promote programs to
prevent obesity.
Prospective Multi-Center Study of Reliability in Vascular Laboratory
Testing of Venous Reflux
F. Lurie, The Kistner Vein Clinic and the University of Hawaii, Honolulu,
Hawaii
